Public Release: 

Mouse model of Duchenne muscular dystropy identifies potential new approaches to therapy


Genetic ablation of P2RX7 can improve muscle function and partially correct cognitive impairment and bone loss in a mouse model of Duchenne muscular dystrophy (DMD), according to a study published this week in PLOS Medicine. The study, conducted by Dariusz Gorecki of the School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK and colleagues, additionally suggests that P2RX7 antagonists can reduce certain DMD phenotypes in these mice.

Duchenne muscular dystrophy comprises muscle waste with chronic inflammation, cognitive and behavioral impairments and low bone density. DMD is caused by mutations in dystrophin, a membrane scaffold protein with a role in protecting muscle fibers from damage during muscle contraction. The function of P2RX7, a purinoceptor that senses ATP released from damaged cells and activates the innate immune response, is altered in dystrophic cells to mediate cell death in the mdx mouse model of DMD and in human DMD. In this study, the researchers investigate whether genetic ablation of P2RX7 can attenuate the DMD symptoms of the mdx mouse model. The researchers found that double mutant mice that make no functional dystrophin or P2RX7 showed improved muscle structure and strength, decreased inflammation, and decreased fibrosis compared to mdx mice. P2RX7 ablation also reduced blood levels of creatinine kinase, cognitive impairment, and bone structure alterations. Finally, aspects of the dystrophic pathology in mdx mice could also be reduced by treatment with P2RX7 antagonists.

The findings show that, in mdx mice, P2RX7 ablation affects multiple disease phenotypes analogous to those of human DMD. However, data from animal models always require validation in human studies. Nonetheless, should the findings translate to human pathology, these results may identify new options for DMD therapies. The authors state, "Given that specific P2RX7 antagonists have been in human trials for other conditions, these could be readily repurposed for treatment of this lethal disease."


Research Article


This work was supported by grants from the Duchenne Parents Project NL ( to DCG, Muscular Dystrophy Association USA (MDA294571; to DCG, and the EU Interreg IV (TC2N; to DV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

The authors have declared that no conflict of interest exists.


Sinadinos A, Young CNJ, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, et al. (2015) P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy. PLoS Med 12(10): e1001888. doi:10.1371/journal.pmed.1001888

Author Affiliations:

Molecular Medicine, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

Departments of Surgery, Immunology, and Bioengineering, School of Medicine, University of Pittsburgh, Pittsburg, Pennsylvania, United States of America

School of Engineering, University of Portsmouth, Portsmouth, United Kingdom

Platform of Behavioural Analysis (SCAC), University of Rouen, Mont-Saint-Aignan,Rouen, France

INSERM U982, Plate-Forme d'Imagerie PRIMACEN, IRIB, University of Rouen, Mont-Saint-Aignan, France

Genomics of Adaptive Immunity Lab, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry and Pirogov Russian National Research Medical University, Moscow, Russia

National Center of Scientific Research (CNRS), Caen, France


Dariusz Gorecki
Professor of Molecular Medicine
University of Portsmouth
Pharmacy and Biomedical Sciences
White Swan Road
Portsmouth, PO1 2DT
FAX: +442392843565

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.